EHRA 2023: Late-Breaking Science Video Collection
Published: 18 April 2023
-
Views:
2309
-
Likes:
7
-
Views:
2309
-
Likes:
7
-
Up Next -
3m 37sPart 1 | Session 6 Conformable PVI Catheter for Pulmonary Vein Isolation -
3m 54sPart 1 | Session 7 BRUGADA Randomized: Epidcardial Ablation to Prevent Sudden Death
-
6m 25sPart 2 | Session 1 5 Trials That Will Change Your Practice With Dr Sohaib -
6m 24sPart 2 | Session 2 4 Trials That Will Change Your Practice With Dr Di Biase
-
54sPart 3 | Session 1 Dr Bergonti: Pulsed-Field Ablation & Reasons to Research -
1m 52sPart 3 | Session 2 Dr Bruce Wilkoff: Therapy Morbidity and Advice to Young Researchers -
31sPart 3 | Session 3 Dr Carlo Pappone: Advice to Early-Career Electrophysiologists -
28sPart 3 | Session 4 Dr Juan Caro Codon: Building a Team For Success -
1m 33s
-
4m 23sPart 1 | Session 1 POTTER: Oesophageal Fistulae in Catheter Ablation Patients Roland R Tilz
-
4m 26sPart 1 | Session 2 AdaptResponse: AdaptivCRT® Algorithm in Synchronized LV Pacing Bruce Wilkoff
-
6m 49sPart 1 | Session 3 MANIFEST-PF: Real-world Experience of PFA in Commercial Practice Vivek Reddy
-
6m 26sPart 1 | Session 4 ANTWOORD II: LVEF Recovery After Atrial Fibrillation Ablation in Heart Failure Patients Marco Bergonti
Overview
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice.
More from this programme
Part 1
Expert Interviews
Part 2
Featured Highlights
In these concise overviews, selected faculty provide their thoughts on the most impactful trials from EHRA 2023.
Part 3
Behind the Heart
Watch our Behind the Heart series to learn more about the personal perspectives of the investigators behind top trials in cardiovascular science.
About the episode
EHRA 2023 — Dr Juan Caro Codón (La Paz University Hospital, Madrid, ES) discusses the findings from the TEMPO-HCM study investigating extended ECG monitoring in hypertrophic cardiomyopathy (HCM) patients.
This was a prospective, observational, multicenter trial that included patients with a diagnosis of hypertrophic cardiomyopathy. Investigators compared the rate of clinically relevant arrhythmias within 30 days vs their first 24 hours with an ECG.
Questions
1. What is the significance of this study and what are the barriers in treating HCM patients?
2. Study design, patient cohort, and outcome measures?
3. Current findings of the study?
4. How should these findings influence practice and guidelines?
5. What are the next steps?
Filmed on-site at EHRA 2023, Barcelona.
Comments